JP2005536447A - Ｔｎｆ−アルファを発現するアデノウイルスベクターを用いるヒト癌の処置 - Google Patents

Ｔｎｆ−アルファを発現するアデノウイルスベクターを用いるヒト癌の処置 Download PDF

Info

Publication number
JP2005536447A
JP2005536447A JP2003541750A JP2003541750A JP2005536447A JP 2005536447 A JP2005536447 A JP 2005536447A JP 2003541750 A JP2003541750 A JP 2003541750A JP 2003541750 A JP2003541750 A JP 2003541750A JP 2005536447 A JP2005536447 A JP 2005536447A
Authority
JP
Japan
Prior art keywords
tumor
pharmaceutical composition
cancer
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541750A
Other languages
English (en)
Japanese (ja)
Inventor
ラスムッセン、ヘンリック、エス．
チュー、カレン、ダヴリュ．
Original Assignee
ジェンベク、インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21693977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005536447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェンベク、インコーポレイティッド filed Critical ジェンベク、インコーポレイティッド
Publication of JP2005536447A publication Critical patent/JP2005536447A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003541750A 2001-11-02 2002-11-01 Ｔｎｆ−アルファを発現するアデノウイルスベクターを用いるヒト癌の処置 Pending JP2005536447A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/001,017 US20030086903A1 (en) 2001-11-02 2001-11-02 Therapeutic regimen for treating cancer
US10/151,633 US7214368B2 (en) 2001-11-02 2002-05-17 Therapeutic regimen for treating cancer comprising the administration of adenoviral vectors comprising a TNF-α transgene
PCT/US2002/035042 WO2003039458A2 (fr) 2001-11-02 2002-11-01 Schema posologique therapeutique utilise dans le traitement du cancer

Publications (1)

Publication Number Publication Date
JP2005536447A true JP2005536447A (ja) 2005-12-02

Family

ID=21693977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541750A Pending JP2005536447A (ja) 2001-11-02 2002-11-01 Ｔｎｆ−アルファを発現するアデノウイルスベクターを用いるヒト癌の処置

Country Status (7)

Country Link
US (5) US20030086903A1 (fr)
EP (1) EP1455840B1 (fr)
JP (1) JP2005536447A (fr)
AT (1) ATE419875T1 (fr)
CA (1) CA2465361A1 (fr)
DE (1) DE60230807D1 (fr)
WO (1) WO2003039458A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011074564A1 (fr) * 2009-12-15 2011-06-23 タカラバイオ株式会社 Procédé de fabrication d'un vecteur d'adénovirus

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8034791B2 (en) * 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
EP1436313B1 (fr) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Constructions de polynucleotides, compositions pharmaceutiques et procedes de regulation negative de l'angiogenese et de therapie anticancereuse
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20040266713A1 (en) * 2003-04-23 2004-12-30 Shan Lu Methods and compositions for solid tumor treatment
US20050027196A1 (en) * 2003-07-30 2005-02-03 Fitzgerald Loretta A. System for processing patient radiation treatment data
ATE458500T1 (de) * 2003-11-14 2010-03-15 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
WO2005079294A2 (fr) 2004-02-12 2005-09-01 Neo Vista, Inc. Methodes et appareil pour une curietherapie intra-oculaire
DE602005024148D1 (de) * 2004-08-25 2010-11-25 Univ Chicago Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
US8586090B2 (en) * 2004-10-05 2013-11-19 Albert Einstein College Of Medicine Of Yeshiva University Melanin nanoshells for protection against radiation and electronic pulses
WO2007059208A2 (fr) 2005-11-15 2007-05-24 Neovista Inc. Procédés et appareils pour une curiethérapie intraoculaire
US10166271B2 (en) * 2006-06-21 2019-01-01 The Regents Of The University Of California Methods for promoting hair growth
CN101960489A (zh) * 2007-12-31 2011-01-26 真实成像有限公司 用于分析热图像的方法、设备和系统
CN101959456A (zh) * 2007-12-31 2011-01-26 真实成像有限公司 用于成像数据的配准的系统和方法
US10299686B2 (en) * 2008-03-28 2019-05-28 Real Imaging Ltd. Method apparatus and system for analyzing images
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
WO2011054811A1 (fr) 2009-11-03 2011-05-12 Santaris Pharma A/S Traitement combiné par des antagonistes d'arn ciblant hsp-27
JP5980117B2 (ja) 2009-11-09 2016-08-31 ジェンヴェック，インコーポレーテッド サルアデノウイルスベクターの増殖方法
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3582183D1 (de) 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1991006658A2 (fr) * 1989-10-24 1991-05-16 Cetus Corporation Systeme d'apport de proteines infectieuses
CA2055168A1 (fr) * 1990-11-21 1992-05-22 Walter Fiers Muteines de tnf
CA2098849C (fr) * 1990-12-20 2007-07-10 Ralph R. Weichselbaum Controle de l'expression de genes par rayonnement ionisant
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5968735A (en) * 1992-11-12 1999-10-19 Max Delbruck-Centrum Fur Molekular Medizin Berlin Vector for the expression of therapy-relevant genes
US5271207A (en) * 1992-11-18 1993-12-21 Moshe Epstein Dual-function nozzle head for vacuum-packaging tooling
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2709309B1 (fr) 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US7592317B1 (en) * 1994-08-11 2009-09-22 The University Of Chicago Constitutive gene expression in conjuction with ionizing radiation
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
AU4994596A (en) 1995-03-01 1996-09-18 Cornell Research Foundation Inc. Interdependent adenoviral vectors and methods of using same
AU5634696A (en) 1995-04-28 1996-11-18 Genetic Therapy, Inc. Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
WO1997012623A1 (fr) 1995-10-06 1997-04-10 Arch Development Corporation Procedes et compositions de stimulation virale d'elimination de cellules
SK72298A3 (en) 1995-11-28 1998-12-02 Genvec Inc Vectors and methods for gene transfer to cells
AU2557097A (en) * 1996-04-17 1997-11-07 Board Of Regents, The University Of Texas System Enhanced expression of transgenes
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
CA2232743A1 (fr) 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
IL120979A0 (en) 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
JP2001518304A (ja) 1997-10-01 2001-10-16 ジー・ディー・サール・アンド・カンパニー アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
DE19747718A1 (de) 1997-10-29 1999-05-06 Baltzer Axel Wilhelm August Dr Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie
AU750803B2 (en) 1997-10-29 2002-07-25 University Of Pittsburgh Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
CA2308575A1 (fr) 1997-11-03 1999-05-14 Tom Tsang Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci
AU762493B2 (en) 1998-03-11 2003-06-26 Board Of Regents, The University Of Texas System Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
WO1999047690A2 (fr) 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Vecteurs multigenes
PT1071805E (pt) 1998-04-24 2011-10-04 Onyx Pharma Inc Vectores adenovirais para tratamento de doença
CA2335038A1 (fr) 1998-06-15 1999-12-23 Arch Development Corporation Combinaison de facteurs radiotherapeutiques et anti-angiogeniques
IL126757A0 (en) 1998-09-07 1999-08-17 Yissum Res Dev Co Regulation of gene expression through manipulation of mRNA splicing and its uses
US6440944B2 (en) 1998-10-16 2002-08-27 Genvec, Inc. Methods of administering adenoviral vectors
WO2000035455A1 (fr) * 1998-12-15 2000-06-22 Telik, Inc. Urees heteroaryle-aryle utilisees comme antagonistes du recepteur igf-1
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
EP1135514B1 (fr) 1999-01-28 2009-05-13 Onyx Pharmaceuticals, Inc. Vecteurs navettes adenoviraux comportant des genes deletes dans la region e1b
WO2001024684A2 (fr) 1999-10-07 2001-04-12 Aguilar Cordova Carlos Estuard Methodes de traitement de tumeurs solides et de metastases par therapie genique
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
JP2004532213A (ja) 2001-04-06 2004-10-21 ザ ユニヴァーシティ オヴ シカゴ Ｅｇｒ−１プロモーター活性の化学療法誘導
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011074564A1 (fr) * 2009-12-15 2011-06-23 タカラバイオ株式会社 Procédé de fabrication d'un vecteur d'adénovirus

Also Published As

Publication number Publication date
US20030086904A1 (en) 2003-05-08
US7214368B2 (en) 2007-05-08
EP1455840B1 (fr) 2009-01-07
WO2003039458A2 (fr) 2003-05-15
EP1455840A2 (fr) 2004-09-15
US20030086903A1 (en) 2003-05-08
US20070166284A1 (en) 2007-07-19
CA2465361A1 (fr) 2003-05-15
US20100305199A1 (en) 2010-12-02
ATE419875T1 (de) 2009-01-15
EP1455840A4 (fr) 2004-12-15
WO2003039458A3 (fr) 2003-11-20
DE60230807D1 (de) 2009-02-26
US20120203052A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
EP1687032B1 (fr) Composition thérapeutique pour le traitement du cancer pancréatique local avancé (lapc).
US20070166284A1 (en) Therapeutic regimen for treating cancer
Zhu et al. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo
KR102229084B1 (ko) 아데노바이러스를 사용하는 치료 방법
JP2003277272A (ja) ＤＮＡ損傷剤およびр５３を含有する組成物
EP1436313B1 (fr) Constructions de polynucleotides, compositions pharmaceutiques et procedes de regulation negative de l'angiogenese et de therapie anticancereuse
US20060140909A1 (en) Method of using adenoviral vectors with increased persistence in vivo
JP4361708B2 (ja) 複製−コンピテント抗癌ベクター
AU2002307793A1 (en) Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
JP2004501650A (ja) 複製欠損アデノウイルスｔｎｆベクター
Sangro et al. Gene therapy of neoplastic liver diseases
WO2005117993A2 (fr) Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers
Lesniak Gene therapy for malignant glioma
AU2002342263A1 (en) Treatment of human cancer with adenoviral vector expressing TNF-alpha
CA2471822C (fr) Vecteur d'expression/replication specifique d'un type de cellule concu a partir du virus herpes simplex comprenant le gene icp4 et le promoteur du gene de la calponine humaine
JP2005530495A (ja) オールターナティブスプライシングされる核酸分子
CA3156880A1 (fr) Adenovirus oncolytiques a replication amelioree
Greenberger et al. 969. Transcription Controlled Gene Therapy Against Tumor Angiogenesis
Ramsay Cancer treatment involving the p53 gene
Parikh et al. 294. Herpes Simplex Virus Mediated Oncolysis is an Effective Intratumoral Therapy in High-Risk Neuroblastoma Tumor Models
Aghi et al. Gene-Based and Viral-Based Therapies

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090324